TRK-IN-31 is an orally active TRK inhibitor with an IC50 of 1.8 nM. It demonstrates excellent antiproliferative activity in Ba/F3-MPRIP-TRKAG667C cells and selectively inhibits TRK kinase activity effectively. TRK-IN-31 also significantly suppresses tumor growth in a Ba/F3-MPRIP-TRKAG667C subcutaneous tumor mouse model.
Target-Kategorie:
Trk receptor
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
